Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
- 31 March 1999
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 46 (3) , 255-265
- https://doi.org/10.1016/s0168-8510(98)00060-8
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- North of England evidence based guidelines development project: guideline for the primary care management of dementiaBMJ, 1998
- Regulating Drug Prices: Where Do We Go from Here?Fiscal Studies, 1998
- North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failureBMJ, 1998
- The use of statins: a case of misleading priorities?BMJ, 1997
- Biotechnology: a special case for health technology assessment?Health Policy, 1997
- Modelling in Ecomomic Evaluation: An Unavoidable Fact of LifeHealth Economics, 1997
- Should Clinical Trials With Concurrent Economic Analyses Be Blinded?JAMA, 1997
- Lessons from international experience in controlling pharmaceutical expenditure III: regulating industryBMJ, 1996
- Fortnightly Review: Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctorsBMJ, 1996
- Industry Comment on the 1995 Revised Australian Pharmacoeconomic GuidelinesPharmacoEconomics, 1996